Updated: MELODEM statement on aducanumab

In response to the recent controversial FDA accelerated approval of aducanumab to treat Alzheimer’s Disease, MELODEM leadership created a statement addressing the need for treatment rollout that is structured to deliver clear and timely evidence on efficacy. This is an updated version of that statement (the former version in past post has been taken down). To read the statement, please view the document below.

MELODEM aducanumab post approval study statement

View all posts